ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2026
Diagnostic performance of staging laparoscopy after chemotherapy and the prognostic impact of peritoneal disease resolution in advanced gastric cancer.
Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe clinical utility of staging laparoscopy (SL) after chemotherapy for advanced gastric cancer remains unclear. This study evaluated the diagnostic performance of post-chemotherapy SL and the prognostic significance of peritoneal disease resolution.
methodsWe retrospectively analyzed 128 patients who underwent SL after chemotherapy. Peritoneal disease was defined as macroscopic peritoneal dissemination and/or positive peritoneal lavage cytology. Diagnostic accuracy, sensitivity, and specificity of post-chemotherapy SL were evaluated. We examined the incidence of newly detected peritoneal disease among patients who were negative before chemotherapy and the rate of peritoneal/cytologic (P/CY) resolution among those who were positive before chemotherapy. Survival outcomes were compared according to post-chemotherapy P/CY status.
resultsThe overall positivity rate of post-chemotherapy SL was 38.3%. Newly detected peritoneal disease on post-chemotherapy SL was observed in 2.8% of initially negative patients; when false-negative cases were considered, the actual rate was 5.6%. Among 92 patients with peritoneal disease before chemotherapy, the true P/CY resolution rate after excluding false-negative cases was 37.0%. Patients who achieved P/CY resolution had significantly better survival than those with persistent peritoneal disease (median survival time, 53.7 vs. 21.5 months). Persistent P/CY positivity was an independent adverse prognostic factor.
conclusionsPost-chemotherapy SL appears to be most useful as a patient selection tool, particularly in patients with peritoneal disease at initial diagnosis, by identifying those who may benefit from subsequent treatment escalation. In contrast, newly detected peritoneal disease was uncommon in initially negative patients. Careful interpretation is required because of the risks of false-negative findings and early peritoneal recurrence.
Indexed as
Identifiers
42223869What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.